Chairman of the Board – Greig Woodring
Lead Director – James Benson
Board Member – William A. Roper
Chief Executive Officer – Tom Wamberg
Chief Scientific and Operating Officer – Mark Winham
Chief Medical Director – Dr. Philip Smalley
Managing Director – Bob Hebron
Managing Director – David Sterzer
Senior VP, Business Development – Lynnette Bates
Senior VP, Business Development – Erin Stalker
Executive VP, Sales & Business Development – Nick Bellanca
A. Greig Woodring, Chairman
Greig Woodring is the retired President and Chief Executive Officer of Reinsurance Group of America, Incorporated (RGA). Prior to assuming the role of President and Chief Executive Officer of RGA in 1993, Greig served as Executive Vice President of General American Life Insurance Company (now GenAmerica Financial L.L.C.) in charge of all reinsurance business.
Greig joined General American in 1979 as an actuary, and assumed responsibility for General American’s reinsurance business in 1986. Before joining General American, he was an actuary at United Insurance Company in Chicago. General American’s reinsurance division led to the formation of RGA, which Greig led through its initial public offering in May 1993. After more than 20 years of his leadership, RGA grew to become one of the world’s leading life reinsurers, with offices in 26 countries and annual revenues of more than $10 billion.
Greig is a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. He received a Bachelor of Science (B.S.) degree in mathematics from the University of Michigan, two years of post-graduate Mathematics study at the University of Illinois and an M.B.A. from Washington University in St. Louis. He also serves as Chairman of Wamberg Genomics Advisors, and as chairman of the International Insurance Society.
James. M. Benson, Lead Director
James M. Benson currently serves as CEO of Benson Botsford, LLC. Jim has held CEO positions with John Hancock, Manulife, The New England, GenAmerica, and The Equitable Companies. Mr. Benson earned a B.A. from the University of Illinois and an M.B.A. from the University of Southern California. He serves on several boards, including the United States Olympic Committee, University of Illinois Foundation and the Hospital for Special Surgery. He is a Founder and Chairman of World T.E.A.M. Sports, an organization dedicated to providing opportunities through sports activities for the disabled.
William A. Roper, Board Member
Bill has significant leadership experience as chief executive officer, chief financial officer, and as a board member and investor in a number high growth companies over the past forty years. He has been involved in both publicly-owned and privately held enterprises involved in diversified technology services, biotechnology, and genomics products.
Bill also has broad experience in corporate mergers and acquisitions, public offerings of both debt and equity, international joint ventures, and numerous billion-dollar-plus financial transactions over the years.
Bill received his B.A. in Mathematics from the University of Mississippi, and he has completed advanced management programs at the Southwestern Graduate School of Banking at SMU and at Stanford University.
Tom Wamberg, Chief Executive Officer
Tom is the CEO of Wamberg Genomic Advisors and is responsible for the overall direction and execution of the company’s strategic plan. In his 30-year career, Wamberg has built and led numerous financial and professional insurance services businesses. Wamberg recently served as President of Insurance and Corporate Business of Human Longevity, Inc. He served as Chairman of Uniphy Health, a secure healthcare collaboration platform for physicians, a company he co-founded in 2013. He previously started and led as Chairman and CEO two other consulting/brokerage companies, Clark & Wamberg, LLC and Clark Inc. (NYSE: CLK) which he took public in 1998. Wamberg is a member of the American College of Healthcare Executives, and is a past president of the Association for Advanced Life Underwriting.
He has also been past president of the 25 Million-Dollar Forum, chairman of the Legislative Task Force and Nonqualified Benefit Plan committee, and has served as a member of the American Society of Pension Actuaries and the Financial Accounting Standards Board. Wamberg is also the author of three books: The Theory and Practice of Bank Owned Life Insurance, The Theory and Practice of Separate Account Bank Owned Life Insurance, and Bank Eligible Alternative Investment Strategies – The Theory and Practice. Tom also holds two patents: 1. System for designing and implementing Bank-Owned Life Insurance (BOLI) with a reinsurance option 2. Method and system for employee and client engagement.
He is a past board member of: The Universidad de las Americas (Mexico City), Students In Free Enterprise (SIFE), Integrated Healthcare Strategies, MEDEX, Baden Retirement Services, Stratford 360, Pearl Meyer & Partners, Stratford Advisory Services, and Wamberg Asset Management. He received his BS from Baldwin Wallace University and serves on the board of the Cleveland Clinic.
Tom has testified before congressional committees on numerous occasions on behalf of the life insurance industry and as Chairman of Clark Consulting was a regular guest on CNBC, MSNBC and CNN as an expert on executive compensation and benefits. He is married to Cindy and they have eight children.
Mark Winham, Chief Scientific and Operating Officer
Mark Winham is WGA’s Chief Scientific and Operating Officer (CSOO), with leadership responsibility for provision of best-in-class offerings, managing global providers, business infrastructure, operational excellence and clinical regulatory compliance. Mark has 30+ years of industry experience, ranging from the clinical laboratory to medical device to life science operations. Previous companies include Sanofi, Johnson & Johnson, Advanced Medical Solutions, Applied Biosystems, Life Technologies, Millennium Health and Human Longevity. He has developed and applied many cellular and molecular biology techniques, and in recent years has worked in the areas of DNA sequencing and genomics.
After early years in the laboratory, Mark gravitated to operations leadership in medical device, life sciences and laboratory based businesses. He has expert knowledge in Product Development, Manufacturing Sciences & Engineering and Order Fulfillment. Moreover, he has extensive international experience at multiple scales of business, from start-up to site management to multi-site global operations; for example, while VP of Global Manufacturing at Life Technologies, Mark was directly responsible for 30+ sites on 5 continents with 2,500+ manufacturing professionals producing 50,000 parts numbers in support of nearly $4Bn of revenue. Mark moved from the UK to the USA in 2004 and is now a permanent resident of the USA.
Mark holds a Bachelor of Science degree in Life Sciences from Napier University in Edinburgh, UK, and a Business Diploma in Company Direction from the Institute of Directors, London, UK.
Dr. Philip Smalley, Chief Medical Director
Dr. Phil Smalley is an Internal Medicine specialist with 27 years of experience in insurance medicine. He recently retired from his position as Senior Vice President and Global Chief Medical Officer for RGA International Corporation. Dr. Smalley received his medical degree from the University of Toronto, Canada. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and Past President of the Canadian Life Insurance Medical Officers Association. Dr. Smalley was also Managing Director of the Longer Life Foundation, the not-for-profit research partnership between RGA and Washington University School of Medicine. Dr. Smalley currently lives in Toronto consulting for the insurance industry and is Chief Medical Director for Wamberg Genomic Advisors.
Bob Hebron, Managing Director
With a background in economics and law, Bob began his career as a trial lawyer, eventually moving to insurance counsel for litigation and emulators matters at Phoenix Mutual. in 1988, Bob joined New York Life becoming its chief insurance counsel and taking responsibility for the defense of class action litigation related to the sale of life insurance in the 1990s. Following that stint he took over product development efforts for New York Life’s COLI and BOLI lines of business in 1996, growing that business from $3 billion in AUM to $20 billion plus in AUM. He finished his career at New York Life responsible for third party distribution management in the life insurance line of business.
David Stertzer, Managing Director
David Stertzer is a Managing Director for Wamberg Genomic Advisors with a focus on life insurance companies and genomic / Advanced DNA Testing program strategies. As top officer at AALU for nearly thirty-three years, Stertzer provided continuity, leadership and strategic vision to AALU’s Board of Directors. Throughout the AALU’s growth period, David stressed the critical nature of a unified life insurance industry to deliver its message to Capitol Hill with a single voice and increase the number of successful members of the life insurance community.
Mr. Stertzer says, “The life insurance community has always innovated. New products and programs have consistently been created that have been critical components in meeting the comprehensive financial, and life needs of insureds. The programs being created by Wamberg are enabling the life insurance community and agents to be at the forefront of programs that extend and improve life. It is consistent with the values and purpose of life insurance. I am excited to be part of this mission to help the life insurance community and their agents make genomics and advanced DNA testing part of their portfolio.”
Lynnette Bates, Senior VP, Business Development
Lynnette is a Senior VP of Business Development for Wamberg Genomic Advisors, Inc., specializing in custom genomic-based product and service offerings for employee benefit brokers and insurance carriers.
Through Lynnette’s extensive background in Sales, Client Management, Marketing and Project Management she provides a strategic and holistic consulting approach for employers, insurance brokers and carriers. Previous companies include Human Longevity, Inc., Unum Insurance and American Express.
She graduated from Arizona State University in 2005 with a Bachelor of Arts in Mass Communications & Media Studies.
Erin Stalker, Senior VP, Business Development
Erin Stalker is a Senior VP of Business Development at Wamberg Genomic Advisors, Inc. She is responsible for the development and support of relationships within the insurance and employee benefits industry. In addition, she works with her team to develop custom genomic offerings for clients and prospects.
Before joining Wamberg Genomic Advisors she served as Senior Market Consultant within the Insurance and Corporate Business Department at Human Longevity, Inc. She educated and consulted members of the insurance community and large corporate businesses regarding genomics and Human Longevity, Inc.’s product portfolio.
She has over 10 years working within the insurance industry.
As a Senior Account Executive for a leading insurance carrier, she focused primarily on selling group and worksite benefits through her established relationships in Southern California. She also provided enrollment and technology recommendations and guidance to her brokers and clients.
Erin graduated with a degree in Applied Nutrition from California Polytechnic State University, San Luis Obispo in 2008, and currently lives with her husband Nick in San Diego, California.
Nick Bellanca, Executive VP, Sales & Business Development
Nick leads the growth and expansion of WGA’s group benefit division, focusing in on brokers, employers, carrier partners, and emerging distribution channels. Prior to joining WGA, Nick was a top, national producer for a Fortune 500 insurance carrier for over 12 years. He partners closely with consultants, enrollment firms, benefits administration providers, and employers on the development and delivery of new and innovative employee benefit programs. Nick holds a B.A. in Accounting from the University of San Diego.